Nektar Therapeutics (LON:0UNL)
42.08
-0.62 (-1.46%)
Dec 31, 2025, 5:12 PM BST
Nektar Therapeutics Employees
Nektar Therapeutics had 61 employees as of December 31, 2024. The number of employees decreased by 76 or -55.47% compared to the previous year.
Employees
61
Change (1Y)
-76
Growth (1Y)
-55.47%
Revenue / Employee
763.45K GBP
Profits / Employee
-1.47M GBP
Market Cap
632.60M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 61 | -76 | -55.47% |
| Dec 31, 2023 | 137 | -79 | -36.57% |
| Dec 31, 2022 | 216 | -524 | -70.81% |
| Dec 31, 2021 | 740 | 22 | 3.06% |
| Dec 31, 2020 | 718 | -5 | -0.69% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| Convatec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| Genus | 3,190 |
| HUTCHMED (China) | 1,811 |
Nektar Therapeutics News
- 12 days ago - Nektar Therapeutics: Rezpeg's Phase 2b Alopecia Areata Results Leave Many Questions - Seeking Alpha
- 13 days ago - Nektar Therapeutics: Alopecia Update And A Look At The Road Ahead For Rezpeg - Seeking Alpha
- 14 days ago - Nektar Therapeutics (NKTR) Discusses Topline Results From REZOLVE-AA Phase 2b Study of rezpegaldesleukin in Alopecia Areata - Slideshow - Seeking Alpha
- 15 days ago - HC Wainwright Raises Price Target for NKTR to $135, Reiterates Buy Rating | NKTR Stock News - GuruFocus
- 15 days ago - Nektar Therapeutics (NKTR) Discusses Topline Results From REZOLVE-AA Phase 2b Study of rezpegaldesleukin in Alopecia Areata Transcript - Seeking Alpha
- 15 days ago - Nektar Alopecia Trial Misses Endpoint, Hits Significance After Patient Exclusion - Benzinga
- 15 days ago - Nektar Alopecia Trial Misses Endpoint, Hits Significance After Patient Exclusion - Benzinga
- 15 days ago - Rezpegaldesleukin Shows Proof-of-Concept In Alopecia Areata, Meeting Efficacy Targets In Phase 2b - Nasdaq